Stay updated with breaking news from Dan Cooper. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A small but rapidly growing number of U.S. adolescents began treatment with Novo Nordisk's weight-loss drug Wegovy last year, a powerful new tool to address record rates of pediatric obesity,...
A small but rapidly growing number of U.S. adolescents began treatment with Novo Nordisk's weight-loss drug Wegovy last year, a powerful new tool to address record rates of pediatric obesity,...
A small but rapidly growing number of U.S. adolescents began treatment with Novo Nordisk's weight-loss drug Wegovy last year, a powerful new tool to address record rates of pediatric obesity, according to data shared exclusively with Reuters.
Rise of adolescent usage of Novo Nordisk's Wegovy for pediatric obesity. Surging demand among families, but concerns linger on the impact of weight-loss drugs on growing children's development.
In March last year, Billy Small Jr. of Oakland, California, was on the cusp of developing type 2 diabetes, weighing in at 385 pounds (176 kilograms) - twice that of the average boy his age.